Emerging evidence and expert consensus continue to refine heart failure management, with a strong focus on early initiation of quadruple therapy—ARNI, β-blocker, MRA, and SGLT2 inhibitor—as the foundation of care for patients with reduced ejection fraction, regardless of diabetes status. Growing data also support the use of SGLT2 inhibitors in heart failure with preserved ejection fraction, helping reduce hospitalizations and improve patient outcomes. Clinicians are encouraged to adopt individualized diuretic strategies and close follow-up to ensure optimal volume control and therapy response.
A multidisciplinary, time-sensitive approach, supported by NT-proBNP testing and point-of-care ultrasound, enables earlier diagnosis and faster therapy optimization to improve survival and quality of life. Are SGLT2 inhibitors now a routine part of your first-line heart failure therapy approach?…
